Raymond James Trust N.A. Makes New $223,000 Investment in DaVita Inc. (NYSE:DVA)

Raymond James Trust N.A. acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,362 shares of the company’s stock, valued at approximately $223,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC bought a new position in shares of DaVita in the third quarter worth approximately $25,000. Blue Trust Inc. boosted its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares during the period. Family Firm Inc. purchased a new stake in DaVita in the 2nd quarter worth $43,000. Versant Capital Management Inc raised its holdings in DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Finally, Friedenthal Financial purchased a new position in shares of DaVita in the second quarter valued at about $48,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Down 1.4 %

Shares of DVA opened at $165.63 on Friday. The stock has a market capitalization of $13.58 billion, a PE ratio of 17.87, a P/E/G ratio of 0.94 and a beta of 0.89. The company’s fifty day moving average is $158.47 and its 200 day moving average is $148.99. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $169.51.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter last year, the firm earned $2.85 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on DVA. Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Finally, Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.